IGC Pharma (IGC) Q4 2025 Earnings
IGC·Reported April 3, 2026·After market close
IGC Pharma reported Q4 2025 revenue of $300.0K (+16.7% YoY), beat analyst consensus of $246.5K by $53.5K. Diluted EPS came in at $-0.01 (+50.0% YoY), beat the $-0.02 consensus by $0.01.
Revenue
$300.0Kbeat by $53.5K
Consensus: $246.5KDiluted EPS
$-0.01beat by $0.01
Consensus: $-0.02
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q4 2025 Earnings FAQ
Common questions about IGC Pharma's Q4 2025 earnings report.
IGC Pharma (IGC) reported Q4 2025 earnings on April 3, 2026 after market close.
IGC Pharma reported revenue of $300.0K and diluted EPS of $-0.01 for Q4 2025.
Revenue beat the consensus estimate of $246.5K by $53.5K. EPS beat the consensus estimate of $-0.02 by $0.01.
Compared to the same quarter a year prior, revenue grew 16.7% from $257.0K a year earlier and diluted EPS grew 50.0% from $-0.02.